Targeting ABCB5 for cancer therapy
AssigneeThe Brigham and Women's Hospital, Inc.
InventorsMarkus H. Frank, Natasha Y. Frank, Mohamed H. Sayegh
Life of this patent
Estimating the term…
Abstract
The invention related to methods for treating a subject by manipulating ABCB5 on a cell as well as related products. The methods include methods of treating cancer using ABCB5 binding molecules such as antibodies and fragments thereof.
Claims12
A method of delivering a therapeutic agent to an intracellular compartment of a cell, comprising:
- contacting a cell with an isolated antibody or peptide that selectively binds to ABCB5 conjugated to a therapeutic agent in an effective amount to deliver the therapeutic agent to an intracellular compartment of the cell.
A method of delivering a therapeutic agent to an intracellular compartment of a cell, comprising:
- contacting a cell with an isolated antibody or peptide that selectively binds to ABCB5 conjugated to a therapeutic agent in an effective amount to deliver the therapeutic agent to an intracellular compartment of the cell, further comprising contacting a cell with an isolated molecule that selectively binds to a surface marker selected from the group consisting of 25 CD49e, CD133, and CD166.
A method of delivering a therapeutic agent to an intracellular compartment of a cell, comprising:
- contacting a cell with an isolated antibody or peptide that selectively binds to ABCB5 conjugated to a therapeutic agent in an effective amount to deliver the therapeutic agent to an intracellular compartment of the cell, further comprising contacting a cell with an isolated molecule that selectively binds to a surface marker selected from the group consisting of BMPR1a, TIE-1, VE-cadherin (CD144) and nestin.
A method for treating a subject, comprising
- systemically administering an isolated peptide that selectively binds to ABCB5 and comprises an amino acid sequence having SEQ ID NO:
- 1 (heavy chain variable region) and SEQ ID NO:2 (light chain variable region) or having the following 6 CDRs:
- SEQ ID NO:3 (CDR-H1), SEQ ID NO:4 (CDR-H2), SEQ ID NO:5 (CDR-H3), SEQ ID NO:6 (CDR-L1), SEQ ID NO:7 (CDR-L2), or SEQ ID NO:8 (CDR-L3), to a subject having cancer in an effective amount to treat the cancer.
A method for treating a subject, comprising
- administering a composition comprising an isolated peptide having 6 CDRs that selectively bind to ABCB5 wherein the isolated peptide comprises SEQ ID NO:
- 1 (heavy chain variable region) and SEQ ID NO:2 (light chain variable region) or has the following 6 CDRs:
- SEQ ID NO:3 (CDR-H1), SEQ ID NO:4 (CDR-H2), SEQ ID NO:5 (CDR-H3), SEQ ID NO:6 (CDR-L1), SEQ ID NO:7 (CDR-L2), or SEQ ID NO:8 (CDR-L3), wherein the isolated peptide is not mAb 3C2-1D12 to a subject having cancer in an effective amount to treat the cancer.
A method for treating a subject, comprising
- administering an isolated peptide that selectively binds to ABCB5 and comprises an amino acid sequence having 6 CDRs wherein the isolated peptide comprises SEQ ID NO:
- 1 (heavy chain variable region) and SEQ ID NO:2 (light chain variable region) or has the following 6 CDRs:
- SEQ ID NO:3 (CDR-H1), SEQ ID NO:4 (CDR-H2), SEQ ID NO:5 (CDR-H3), SEQ ID NO:6 (CDR-L1), SEQ ID NO:7 (CDR-L2), or SEQ ID NO:8 (CDR-L3), and a chemotherapeutic agent, to a subject having cancer in an effective amount to treat the cancer.
A method for treating a subject, comprising
- systemically administering an isolated antibody or antibody fragment that selectively binds to ABCB5 and a chemotherapeutic agent to a subject having cancer in an effective amount to treat the cancer.
Dependencies are inferred from the claim text.